Rossari Biotech files unaudited Q2 FY2026 results (standalone & consolidated)

What Rossari Biotech announced

On 18 July 2026, Rossari Biotech Ltd (BSE: 543213) submitted its unaudited financial results for the quarter ended 30 June 2026. The filing, made through the Bombay Stock Exchange’s corporate portal, contains both standalone and consolidated statements for the period. The results are presented on an unaudited basis, pending the completion of the statutory audit.

"The company has filed its unaudited financial results for the quarter ended 30 June 2026, covering both standalone and consolidated financial statements."

The announcement does not provide any quantitative details such as revenue, profit before tax, or earnings per share. Interested investors are directed to the full PDF filing for the complete set of numbers.

Details of the filing

• Filing date: 18 July 2026 (11:16:42 UTC)
• Regulatory platform: Bombay Stock Exchange (BSE)
• Document type: Unaudited Financial Results – Standalone and Consolidated
• Reporting period: Quarter ended 30 June 2026 (Q2 FY2026)
• Company identifiers: Rossari Biotech Ltd, BSE code 543213 (no NSE listing disclosed)

The filing complies with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, which mandate that listed entities disclose quarterly results within 45 days of the quarter’s end. By filing on 18 July, Rossari Biotech remains within the prescribed timeline.

Key facts at a glance

Why this matters for investors

The filing confirms that Rossari Biotech is adhering to its disclosure obligations, providing transparency on its quarterly performance. While the numbers are unaudited, the release signals that the company is on track to complete its audit and publish final figures later in the fiscal year. Investors can use the unaudited data to gauge short‑term operational trends, but should await the audited results for definitive financial assessment.

Key considerations include:

• Timing: The filing is within the statutory window, reducing regulatory risk.
• Audit status: As the results are unaudited, there remains a possibility of adjustments after the audit.
• Access to details: The full PDF contains the granular financial tables; the summary here does not disclose them.

Conclusion

Rossari Biotech Ltd has fulfilled its quarterly reporting requirement by filing unaudited standalone and consolidated results for Q2 FY2026 on 18 July 2026. The filing provides the regulatory baseline but does not disclose specific financial metrics. Investors should review the complete PDF for detailed numbers and await the audited statements for final confirmation of the company’s performance.